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Recent  advances  in  tissue  culture  technology and  the  derivation  of T  cell 
clones have led to the generation and extended culture in vitro of a wide variety 
of antigen-specific  T  cell  clones  (1,  2).  Virus-specific  murine  T  cell  clones 
exhibiting either a helper or cytolytic phenotype have been shown to function in 
vivo in  several  model  systems, including those  for  cells  infected by  influenza 
virus (3), herpes simplex virus (4), and Sendai virus (5), and tumor cells induced 
by  Abeison  leukemia  virus  (6)  or  Moloney  murine  sarcoma  virus-Moloney 
murine leukemia virus (M-MSV-M-MLV) l (7).  In spite of several recently pub- 
lished reports (8-10),  it is still unclear what target molecule(s) is recognized by 
cytolytic T  lymphocytes (CTL) directed against M-MSV-M-MLV-infected target 
cells. Most studies have used mixed populations of CTL and did not allow one 
to distinguish if the CTL recognizes an antigen encoded by M-MSV-M-MLV or 
a  cellular  antigen  induced  as  a  result  of the  infection.  In  the  former  case, 
candidate molecules are the envelope glycoproteins gp70  and p15  (E) and the 
gag membrane proteins gP85 gag and gP95 g~g (gP95 g~g being the precursor protein 
of gP85gag;  11,  12).  Investigators using purified gp70 or anti-gp70 antibodies to 
block CTL recognition of target cells have obtained contradictory results (9,  13, 
14).  Experiments using recombinant  DNA  clones to transfect target cells and 
yield the expression of gp70 and pl 5 (E) demonstrated the existence of a subset 
of BALB/c (H-2 d) M-MLV-specific CTL able to recognize these molecules (10). 
In this report we have characterized gP85 g~g as a  target molecule expressed on 
M-MSV-M-MLV- or M-MLV-infected cells recognized by the Lyt-2  + M-MSV- 
M-MLV-specific CTL clones under investigation. The in vivo activity of these 
CTL clones was tested in two systems. (a) CTL clones were used in long-term 
protection studies in mice injected intraperitoneally with M-MLV-induced tumor 
cells. 30-60 d after injection of tumor cells and the CTL clone, we observed the 
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growth of antigen-loss variants in certain mice that were initially protected against 
tumor formation (7).  After cloning in  vitro,  these tumor cells were no longer 
iysed by the CTL clones or by mixed leukocyte-tumor cell populations (MLTC). 
After several months of culture in vitro, two of five of these antigen-loss variants 
reverted to the original CTL-susceptible phenotype. Both the CTL-nonsuscep- 
tible and -susceptible variants were characterized on the molecular level. (b) We 
obtained long-lasting protection against  tumor formation induced by M-MSV- 
M-MLV injection in syngeneic mice after intravenous injection of the same virus- 
specific CTL clones. 
Materials and Methods 
Mice.  C57BL/6 (H-2b), DBA/2 (H-2d), and BALB/c (H-2  d) female mice were obtained 
from the animal colony of the Swiss Institute for Experimental Cancer Research. The 
breeding pairs for this colony originated from The Jackson Laboratory, Bar Harbor, ME. 
Cells  and  Viruses.  MBL-2 (H-2  b) and a  subclone MBL-2.9, and  LSTRA (H-2d),  all 
M-MLV-induced lymphomas,  were  maintained  by passage  as  ascites in  C57BL/6  and 
BALB/c mice, respectively (15).  They were labeled with SlCr and used as target cells in 
5~Cr release assays as described (15), with one lytic unit (LU) equal to that number of 
effector cells required to give 50% lysis of 10  ~ labeled target cells in 3.5 h at 37°C (16). 
L cells, A-9 cells, (an M-MLV-infected NIH-3T3 cell line), and Ab-X-MLV-infected NIH- 
3T3 cells (17) were grown in Duibecco's modified Eagle's medium supplemented with 
10% fetal calf serum and antibiotics. Murine embryo fibroblasts (MEF) were prepared 
from 15-d-old C57BL/6 embryos and used as a second or third passage. Infection of cells 
was performed in the presence of 4 ~g]ml polybrene. B cell lymphoblasts were prepared 
(18) and infected with virus as described previously (19). 
Cell Labeling and Immunoprecipitations.  Cells were labeled with [sSS]methionine (100 
#Ci/ml)  for  1 h,  washed  with  phosphate-buffered saline  (PBS),  and  iysed in  a  buffer 
containing PBS, 1% Triton X-100, 0.5% deoxycholate, and 0.1% sodium dodecyl sulphate 
according to Van Zaane et ai. (20). Viral proteins were immunoprecipitated from cleared 
lysates by incubation of portions of the lysates (500,000 cpm) first with antisera directed 
against Rauscher MLV p30 or gp70 (obtained from the National Cancer Institute) and 
second with protein A-Sepharose, as described (21). Immunoprecipitates were analyzed 
by electrophoresis on  10%  SDS-polyacrylamide gels and radioactivity was visualized by 
exposure of EN~HANCE-treated gels to Kodak XAR-5 film. 
Generation  of M-MSV-M-MLV-specific  CTL  Clones.  M-MSV-M-MLV-specific  CTL 
clones were derived from C57BL/6 regressor mice by micromanipulation techniques as 
described (22,  7).  Lyt-2  ÷ CTL clones that demonstrated vigorous growth and  strong 
specific cytolytic activity when tested on MBL-2.9 target cells were selected for in vivo 
protection studies (7). MLTC cultures, which served as a source of an M-MSV-M-MLV- 
specific CTL population, were set up as reported previously (15). C57BL/6 anti-DBA/2 
CTL clones were derived by micromanipulation of immune peritoneal exudate lympho- 
cytes obtained from primed C57BL/6 mice as described (7). 
In Vivo Protection Studies.  The potential for M-MSV-M-MLV-specific CTL clones to 
protect mice against M-MSV-M-MLV-induced tumors was studied in two ways: (a) 4-wk- 
old normal or irradiated (650 rad) C57BL/6 female mice were injected in the rear right 
footpad with 40 ttl of a  stock preparation of M-MSV-M-MLV (7).  At the same time, 
various numbers of an M-MSV-M-MLV-specific CTL clone were injected intravenously 
and the mice monitored for tumor growth by measurement of footpad thickness using a 
6  131  Vernier caliper (Etalon, Rolle, Switzerland). (b) In a second approach, 2 ×  10  I-uridine 
(lSq-UdR)-labeled MBL-2.9 tumor cells were injected intraperitoneaily with the simulta- 
neous intravenous injection of 20 X 106 M-MSV-M-MLV-specific CTL clone cells. Tumor 
cell destruction was  monitored by whole-body counting techniques (23).  In additional 
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numbers of nonlabeled MBL-2.9 tumor cells were injected intraperitoneally, followed by 
20 ×  10  6 cells of an active CTL clone intravenously. 
Isolation of Antigen-Loss Tumor Cell Variants.  In  the  long-term  protection  studies 
described above, some mice developed ascites 30-60 d after tumor cell and CTL clone 
injection. Ascites cells were harvested from such mice, washed, and cloned by microma- 
nipulation into single flat-bottom microwells without added filler cells. Those tumor cell 
lines which grew out after cloning (HEMO-4, 10s-2, and 10s-5 derived from MBL-2; and 
1/7.1 and 1/7.2 derived from MBL-2.9) were then tested for the ability to serve as target 
cells for M-MSV-M-MLV-specific CTL populations.  In  certain cases,  the antigen-loss 
tumor cell clones derived in vitro were readapted to growth as ascites and retested in the 
I-UdR whole-body counting assay system. 
DNA and RNA Analysis.  Cellular DNA was isolated and analyzed by Southern hybrid- 
izations as described (24).  Restriction enzymes (Boehringer Mannheim)  were  used as 
described by the manufacturer. The DNA probes used in hybridizations were prepared 
as follows: DNA of plasmids MS-2 and MS-3 (24) was digested with Pst I; the inserts were 
isolated and self-ligated, yielding concatamers of up to eight times the insert's size. These 
products were nick-translated with [s~p]dATP (3,000 Ci/mmol) to specific activities of 7 
×  108 cpm/t~g.  Cytoplasmic RNA was isolated as described (25).  M-MLV-specific RNA 
was detected in Northern hybridizations using the MS-2 probe (25). 
Results 
Target Molecule  Recognized  by M-MSV-M-MLV-specific CTL Clones.  The mol- 
ecule recognized by the Lyt-2  ÷ CTL clone CHM-14 that is specific for antigens 
induced by the oncogenic virus complex, M-MSV-M-MLV  (7), is expressed on 
the  surface  of virus-infected but  not  uninfected  cells.  To  characterize  target 
molecules, we  used the  Ab-X-MLV  mutant  virus,  which was derived from M- 
MLV  by molecular recombination  (17).  As  shown  in  Fig.  1,  M-MLV  harbors 
three genes, of which the first one, gag, codes for the precursor proteins gPr80  g~g 
and  Pr65  (26).  gPr80 g~g is  processed  to gag  membrane  proteins  gP85 gag and 
gP95 gag, while Pr65 is processed to p15, p12, p30, and pl0, which are found in 
the virion core. The Ab-X-MLV mutant, which harbors a point mutation in the 
gag  gene,  can  no  longer  produce  gPr80 g~g but  is  able  to  synthesize all  other 
M-MLV-encoded proteins (17).  C57BL/6  "B lymphoblasts" and  C57BL/6 mu- 
rine embryo fibroblasts  (MEF)  were  mock-infected or infected with either  M- 
MLV  or  Ab-X-MLV.  Cell  cultures  were  examined for the  synthesis  of virus- 
related proteins and  for susceptibility to lysis by CTL clones. As shown in  Fig. 
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FIGURE  1.  Location of the M-MLV-specific DNA probes on the M-MLV restriction map. 
The locations of  the M-MLV-specific  DNA probes MS-2 and MS-3 were determined previously 
(24)  and  are  indicated. Also shown are  the  recognition sites for the  following restriction 
enzymes: Kpn.I (K), Pst I (P), Pvu II (Pv), and Sac I (S) (26). The location of the three viral 
genes gag, pol, and env, with respect to the M-MLV physical map, was according to reference 
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FIGURE 2.  gag Membrane precursor proteins in virus-infected cells. Cells, labeled metabol- 
ically with [sSS]metbionine  for 1 hr, were lysed immediately (B and C) or after a chase period 
of 4 h (A). Viral proteins were analyzed by immunoprecipitations, using anti-gp70 antiserum 
(A) or anti-p30 antiserum (B and C), and electrophoretic separation on 10% SDS-polyacryl- 
amide gels. ENSHANCE-treated  gels were exposed for 1 wk (A and C) or for 1 d (panel B) to 
Kodak XAR-5 film. The precipitated proteins originated from uninfected MEF (lanes a and 
e), M-MLV-infected MEF (b, d, and g), Ab-X-MLV-infected MEF (c, f, and h), and  1/7.2R 
cells (i). 
2, MEF did not synthesize proteins recognized by anti-gp70 or anti-p30 antisera 
(A,  lane  a  and B,  lane  e).  In  M-MLV-infected  MEF,  gPr80  gag, Pr65,  and  p30 
were  detected  using  anti-p30  antiserum  (Fig.  2B,  lane  d).  In  contrast,  Ab-X- 
MLV-infected MEF synthesized Pr65 and low amounts of p30 (Fig.  2, B  lanef 
and  C  lane  h)  but  no  gPr80  g~g. As  shown  in  Table  I,  the  M-MSV-M-MLV- 
specific CTL clones efficiently lysed M-MLV-infected B  lymphoblasts or MEF, 
but not mock-infected or Ab-X-MLV-infected cells. The observed difference in 
sensitivity  to  lysis  of B  lymphoblasts  vs.  MEF  by  CTL  is  most  likely  due  to 
differences  in  inherent  susceptibility  to  lysis  (16).  Ab-X-MLV-  and  M-MLV- 
infected MEF  showed indistinguishable  patterns  of synthesis of the  env  gene- 
encoded proteins gp70 and pl 5 (E) (Fig. 2A, lanes c and b). Therefore, although 
we cannot rule out an  undetected role of gp70 in  the recognition of the target 
cells  by  CTL,  it  is  unlikely  that  gp70  or  p15  (E)  themselves  serve  as  target 
molecules. Thus, these results suggest that the CTL clones specifically recognized 132  CHARACTERIZATION  OF  gP85  g~g 
TABLE  I 
C57BL/6 M-MSV-M-ML V-specific CTL Clones Recognize a gag Gene Product on Virus- 
infected Primary Tissue Culture Target Cells 
Exp. 
Percent specific 5~Cr release 
CTL clone/target cell  Mock-infected  M-MLV-infected  Ab-X-MLV- 
combination  infected 
0.3:1"  1:1  3:1  0.3:1  1:1  3:1  0.3:1  1:1  3:1 
A  C57BL/6"Blymphoblasts" 
with CTL clones: 
CHM-14*  1  1  3  36  65  81  8  10  12 
MOM-I.2  1  2  2  58  77  97  3  6  18 
MOM-2.5  1  2  4  57  68  79  4  10  22 
C57BL/6 embryo fibroblasts 
with CTL clone 
CHM-  14  ~  1  1  4  13  29  41  2  5  11 
"B lymphoblasts" and murine embryo fibroblasts were prepared and infected with virus as described 
in Materials and Methods. 
* Effector-to-target  cell ratio, 4 h incubation. 
* Clone CHM-14 gave 155  LU/106 tested on MBL-2.9 target cells. 
0 Clone CHM-14 gave 103  LU/106 tested on MBL-2.9 target cells. 
the  gag-related  membrane  protein  gP85  gag,  encoded  by  M-MLV,  of  which 
gPr80 gag is the precursor protein. 
Isolation  of Antigen-Loss  Tumor Cell  Variants after lmmunotherapy  With a  CTL 
Clone.  A  modest  protection  against  tumor  formation  was  observed  in  our 
previous studies  (7),  in  which  2  x  106  M-MLV-induced  MBL-2.9  tumor  cells 
were injected  intraperitoneally,  followed by intravenous  injection of 20  ×  106 
CTL clone CHM-14.  When  lower numbers  of MBL-2.9 cells were injected,  a 
much  more significant  long-term  survival of mice was observed (up to  150  d 
after  injection).  However, after  1-2  mo,  certain  mice  that  had  been  initially 
protected  developed ascites.  Tumor  cells  of such  mice  were  cloned  in  vitro, 
labeled with  5~Cr, and  tested for their ability to serve as target  cells for virus- 
specific CTL  clones.  As shown  in  Table  II,  several of the antigen-loss  variant 
tumor cell clones were no longer lysed by either  the virus-specific CTL clones 
or an  M-MSV-M-MLV-specific MLTC population.  We determined that  these 
antigen-loss variants expressed unaltered  levels of H-2  b surface alloantigens,  as 
tested  using  monoclonal  antibodies  and  cell  sorter  analysis  (data  not  shown). 
Furthermore,  we show that they are lysed by allogeneic BALB/c anti-C57BL/6 
MLC cells containing  CTL directed against C57BL/6 H-2  b alloantigens (Table 
II). 
Transcriptionally  Silent  M-MLV Genomes  in Antigen-Loss  Variants.  Several of 
the CTL-resistant antigen-loss tumor cell variants were examined for expression 
of M-MLV gag-related  proteins.  All of the variants were negative for M-MLV 
protein expression compared with the parental tumor cell line (data not shown). 
This phenotypic change could be due to loss of M-MLV genomes or to absence 
of expression of M-MLV DNA. Three independent antigen-loss variants,  1/7.1, 
1/7.2,  and  HEMO-4, were examined  in detail with  the  M-MLV-specific DNA VAN  DES  HOORN  ET  AL. 
TABLE  II 
Characterization of M-MLV Antigen-Loss Tumor Cell Variants Using Various CTL 
Effector Cells 
133 
Effector cell population 
Target cell lysis (LU/106) 
MBL-2  105-5  105-2  HEMO-4  MBL-2.9  1/7.1  1/7.2 
M-MSV-M-MLV-specific  330  300  0.3  0.3  370  0.3  0.3 
CTL clone CHM-14 
M-MSV-M-MLV-specific  15  10  0.3  0.3  30  0.3  0.3 
MLTC population 
BALB/c anti-C57BL/6 al-  22  25  22  17  71  42  36 
logeneic MLC 
105-5,  105-2, and HEMO-4 are tumor cell clones derived by micromanipulation  from the peritoneal 
cavity of mice initially protected against  MBL-2 tumor cells. 105-2 and  105-5 originated from the 
same mouse. 1/7.1 and 1/7.2 are tumor cell clones derived by micromanipulation  from the peritoneal 
cavity of a mouse initially protected against MBL-2.9, a subclone of MBL-2. 
FIGURE 3.  Analysis of M-MLV  genomes in  antigen-loss  variants  and in  a revertant.  The 
presence of M-MLV-specific DNA in antigen-loss  variants,  parental tumor cell lines, and in 
the revertant  1/7.2R cell line was examined by hybridizations  of Southern blots (25) of gel- 
separated,  Kpn I-digested DNAs using the nick-translated,  M-MLV-specific MS-2 probe (24). 
The methylation  patterns of M-MLV genomes were analyzed  by comparing Kpn I/Hpa II- 
and  Kpn  I/Msp  1-restricted  DNAs using  the  same  probe.  Radioautographs of hybridized 
filters  were made on Kodak  XAR-5 film and photographed. The sources  of DNA and the 
restriction  enzymes were: Kpn I-digested MBL-2.9 DNA (lane a); Kpn I-digested 1/7.1  DNA 
(b); Kpn I-digested 1/7.2 DNA (c); Kpn I-digested HEMO-4 DNA (d); L cell DNA digested 
with either Kpn I (e), Kpn I/Msp I (f), or Kpn I/Hpa II (g); 1/7.2R DNA digested  with Kpn 
1 (h), Kpn I/Msp I (i), or Kpn I/Hpa II (j); and MBL-2.9 DNA digested  with Kpn I (k), Kpn 
1/Msp 1 (l), or Kpn I/Hpa ll (m). An Eco RI/Hind II1 digest of bacteriophage ~ DNA served 
as marker. 
probes  MS-2  and  MS-3,  which  previously  had  been  used  to  detect  M-MLV- 
specific DNA restriction  fragments (24). The  location of these DNA probes with 
respect to the M-MLV restriction  map is indicated  in Fig.  1. Cross-hybridization 
of MS-2  with  the  long terminal  repeats  (LTR) of endogenous  MLV present  in 
mouse DNA (27) was observed, while no such cross-hybridization  was found for 
MS-3.  To  distinguish  the  M-MLV  LTR  from  LTR  of endogenous  MLV,  using 
MS2  as  probe,  DNA  of the  three  variants  and  of MBL-2.9  was  digested  with 
Kpn  I, which  generated  a  1.3  kilobasepair  (kbp) fragment recognized with  MS- 
2, which is diagnostic for M-MLV (24). The  endogenous MLV DNA give rise to 
fragments  of 1.5  and  1.8  kb  upon  digestion  with  Kpn  I, recognized  with  MS-2 
(27).  As shown  in  Fig.  3,  b-d,  all  three  variants  retained  M-MLV  genomes,  as 
indicated by the presence of the  1.3 kbp Kpn I fragment, which was also detected 134  CHARACTERIZATION OF gP85  og 
in Kpn I-digested MBL-2.9 DNA (Fig. 3a). In contrast, M-MLV-negative mouse 
cells (L cells) only harbor the  1.5 and  1.8 kbp fragments (Fig.  3e).  Using MS-3 
as a probe, we observed the 2.9 kbp Kpn I M-MLV fragment in the antigen-loss 
variants (not shown). However, the size analysis of RNA synthesized in MBL-2.9 
cells (Fig.  4a)  and  in  the  antigen-loss  variants  (Fig.  4,  b-d)  revealed  M-MLV 
RNA in the parental  tumor cell line only. The  8.2 kb genomic RNA has been 
previously shown (12) to serve as the mRNA forgag andgag-pol protein products, 
while the 3.2 kb RNA species is translated into env gene products. The absence 
of measurable  amounts  of viral  RNA  suggests  that  the  antigen-loss  variants 
retained transcriptionally  inactive M-MLV copies. The remaining  lanes in Figs. 
3 and 4 are the results of experiments described below. 
Reversion  iof Antigen-Loss  Variants  to  CTL-susceptible  Phenotype.  Upon  pro- 
longed  culture  in  vitro  (3  mo),  two of the  five cloned  antigen-loss  tumor  cell 
variants reverted back to their original phenotype, i.e., they were again lysed by 
the  virus-specific  CTL  clone  CHM-14  when  tested  in  a  5~Cr release  assay, 
suggesting  the  reexpression  of M-MLV  genomes  in  these  cells.  One  of these 
CTL-susceptible revertants  (1/7.2,  tested on  February  16,  1984,  hereafter  re- 
ferred to as  1/7.2R) (Fig.  5) was analyzed at the molecular level. A preliminary 
DNA analysis had revealed that the  1/7.2R cells harbored an amplified number 
of M-MLV genomes, which might be responsible for the expression of M-MLV 
genomes.  To quantitate  this result and to examine  the state of methylation of 
the M-MLV genomes, we performed experiments comparing  1/7.2R and MBL- 
2.9  cells  as  well  as  L  cells,  which  do  not  harbor  M-MLV  genomes.  For  the 
methylation studies we used selective inhibition of the restriction enzyme Hpa II 
by methylation of the second cytosine in the recognition sequence CCGG. The 
isoschizomer Msp I  cleaves this sequence regardless of the state of methylation 
(28). DNA of the three cell lines was digested with Kpn I, Kpn I/Hpa II or Kpn 
I/Msp I  and analyzed using the  MS-2 probe (Fig.  3).  As expected, the  1.3  kbp 
Kpn  I  M-MLV fragment detected in  1/7.2R (Fig.  3h) and  MBL-2.9 cells (k) is 
absent from  L  cells (e).  Densitometric  scanning  of lanes h and k revealed that 
FIGURE 4.  Absence of expression of M-MLV-specific RNA in antigen-loss variants. Cyto- 
plasmic RNA was isolated from MBL-2.9 cells (a and e), 1/7.1 cells (b and f), 1/7.2 cells (c), 
HEMO-4 cells (d and h). and  1/7.2R cells (g). RNA were denatured in glyoxal/dimethyl 
sulfoxide, separated electrophoretically on agarose gels, transferred to nitrocellulose filters, 
and hybridized to nick-translated M-MLV-specific  MS-2 probe (25). Autoradiographs were 
prepared and photographed. Ribosomal RNA served  as markers. VAN DER HOORN  ET  AL.  135 
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FIGURE 5.  Reversion of antigen-loss variants to a CTL-susceptible phenotype upon passage 
in vitro. All target cells were tested using CTL clone CHM-14 under standard 51Cr release 
assay conditions (16). (a) Antigen-loss tumor cell variants 1/7. l and 1/7.2 were cloned in vitro 
by micromanipulation of tumor ceils obtained from the peritoneal cavity of a mouse initially 
protected against  MBL-2.9  tumor  cell growth  by  the  intravenous  injection of CTL clone 
CHM-14. (A) 1/7.1 tested on 6 September, 1983; (l-l) 1/7.2 tested on 6 September, 1983; (O) 
MBL-2.9 tested  on 6  September,  1983;  (&)  1/7.1  tested on  16  February,  1984;  (m)  I/7.2 
tested on  16  February,  1984.  (hereafter called  1/7.2R).  (B) Antigen-loss tumor cell variant 
105-2 and the susceptible tumor  10s-5  were cloned in vitro from a  mouse initially protected 
against MBL-2 tumor cells using CTL clone CHM-14. (O)  10s-2  tested on  1 June,  1983; (x) 
MBL-2 tested  on  1 June,  1983;  (<>) 105-5 tested  on  1 June,  1983;  (0)  10=-2 tested  on  6 
September,  1983; (0)  10s-5 tested on 6 September, 1983. 
1/7.2R  yielded approximately eight times more of the  1.3  kbp fragment than 
did  MBL-2.9,  in  contrast  to  1/7.2  cells,  which  contained  as  many  M-MLV 
genomes as did MBL-2.9 cells (Fig. 3, a  and c).  Digestion of 1/7.2R and MBL- 
2.9 DNA with Kpn I/Msp I produced a 0.7 kbp fragment detectable with MS-2, 
which was amplified eight times in 1/7.2R cells (Fig. 3, i and 1), whereas no such 
fragment was found in L  cell DNA (f).  Digestion with Kpn I/Hpa  II yielded 
0.7 kbp fragments in 1/7.2R and MBL-2.9 DNA (Fig. 3,j and m), but not in L cell 
DNA (g), indicating the presence of nonmethylated M-MLV genomes in 1/7.2R 
and MBL-2.9 cells. Upon digestion of 1/7.2R DNA with Kpn I/Hpa II, we also 
observed the 1.3 kbp Kpn I fragment (Fig. 3j), indicating the presence of some 
methylated M-MLV genomes in these cells. Consistent with the detection of an 
amplified number of nonmethylated M-MLV copies in 1/7.2R cells, we observed 
the expression of the 8.2 and 3.2 kb M-MLV-related RNA species in these cells 
(Fig. 4g), but not in the antigen-loss variants  1/7.1  and HEMO-4 (Fig. 4,fand 
h). 
Expression  of an Aberrant gag Precursor Protein in 1/7.2R Cells.  The suscepti- 
bility of the 1/7.2R cells to lysis by CTL clone CHM-14 as well as the expression 
of M-MLV-specific  mRNA  suggested that  these  tumor cells reexpressed gag- 
related membrane proteins. The precursor of these proteins was characterized 
by  metabolic  labeling of  1/7.2R  cells and  immunoprecipitation with anti-p30 
antiserum  (Fig.  2,  panel  C).  M-MLV- and  Ab-X-MLV-infected  MEF  were in- 
cluded as controls: these cells synthesized, respectively, gPr80 g~g, Pr65 and p30 
(Fig. 2C, lane g) and Pr65 and p30 (lane h). In  1/7.2R cells, Pr65 and p30 as 
well as large amounts of a  new gag-related  protein,  Pr92,  were detected (Fig. 
2 C, lane i); surprisingly, no gPr80 gag was observed in these ceils. Also, whereas 
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of the Prl80 gagp°l doublet, which is related to Pr65  (Fig. 2C,  lane h),  M-MLV- 
infected MEF and 1/7.2R cells expressed both species of Prl80 gagp°l (12) (lanes 
g  and i).  Apparently,  the M-MLV genomes that are  expressed  in  1/7.2R  cells 
have  undergone  a  mutational  event  in  vitro,  leading to  the  disappearance  of 
gPr80 g~g and its replacement by Pr92,  but  leaving the synthesis of Pr65  unaf- 
fected. 
gag Region Recombination in 1/7.2R M-MLV Genomes.  We attempted to deter- 
mine the region of the 1/7.2R M-MLV genomes in which the mutation occurred 
by  DNA  analysis using  MS-3  as a  probe.  MS-3  is  specific for  the  N-terminal 
region of the M-MLV gag gene (Fig.  1) (24).  In preliminary experiments using 
MS-3 to detect the 2.9 kbp Kpn I M-MLV fragment, we unexpectedly observed 
the presence of an additional fragment of 3.2 kbp in  1/7.2R  DNA,  suggesting 
the insertion of 300  bp of DNA in the 2.9  kbp Kpn I  region of some M-MLV 
genomes in 1/7.2R cells. A restriction enzyme analysis was carried out to identify 
the site of insertion (Fig. 6). Digestion of 1/7.2R DNA with Kpn I/Sac I, Kpn I/ 
Pvu II, or Pvu II/Pst I generated fragments that were detected with MS-3 of 2.6 
and  2.9  kbp  (Fig.  6a),  1.5  and  1.8  kbp  (b),  and  0.65  kbp  (c),  respectively. 
Digestion of L  cell DNA with the same combinations of enzymes did not yield 
fragments detectable with MS-3 (Fig. 6, d-f). Consistent with previous data (24), 
digestion  of MBL-2.9  DNA  with  Kpn  I/Sac  I,  Kpn  I/Pvu  II,  or  Pvu  II/Pst  I 
generated fragments of, respectively, 2.6,  1.5, and 0.65 kbp (not shown). Based 
on the M-MLV restriction map and the location of the MS-3 probe (see Fig.  1), 
we conclude that the 300 bp insertion event occurred in the gag region between 
the Kpn I site in the 5' LTR and the two Pst I sites. Nucleotide sequence analysis 
of this fragment of M-MLV DNA has shown (26) that the N-termini of gPr80 g~g 
and Pr65  are located in this region,  although the precise  initiation site of the 
FIGURE 6.  Localization of a DNA insertion in M-MLV genomes in 1/7.2R cells. For the 
localization of the 300 bp DNA insertion in the gag region of M-MLV genomes in 1/7.2R 
cells, which are susceptible to lysis  by M-MSV-M-MLV-specific  CTL clones, DNA from 1/ 
7.2R cells (a, b, and c) and L cells (d, e, and  f) was digested with Kpn I/Sac I (a and d), Kpn 
I/Pvu II (b and e), or Pvu II/Pst I (c and f). Restricted DNA were analyzed as described in 
Fig. 3, using a nick-translated, M-MLV-specific  MS-3 probe (24) and the same marker DNA. VAN  DER  HOORN  ET  AL.  137 
gPr80  gag N-terminus remains to  be determined. The  size  difference between 
Pr92 and gPr80  gag can be accounted for by translation of the 300 bp DNA insert 
during the synthesis of gag-related  proteins in 1/7.2R cells. Since the size of Pr65 
was not altered in  1/7.2R cells, we conclude that the insertion event took place 
in a region of the M-MLV genome that codes exclusively for the gag membrane 
precursor protein. 
Inhibition of Virus-induced  Tumor Formation by the Intravenous  Injection of Virus- 
spec~c CTL Clones.  To study the potential protective effects in vivo of the CTL 
clones that  specifically recognize gag-related  membrane proteins on  M-MLV- 
infected target cells, mice were injected simultaneously with M-MSV-M-MLV in 
the footpad and  injected intravenously with  20  ×  10 6  of either virus-specific 
cloned CTL, syngeneic irradiated spleen cells, or anti-H-2d-specific cloned CTL 
(Fig. 7).  Mice injected with virus and with spleen cells developed tumors in the 
footpad and died.  In contrast, the intravenous injection of virus-specific CTL 
clones  CHM-14,  MOM-I.1,  or  MOM-2.1  resulted  in  a  complete,  long-lived 
protection against tumor induction in C57BL/6 mice that had been sublethally 
irradiated (650  rad)  16  h  before injection (Fig.  7, A and B).  The injection of 
another group  of mice with  20  ×  10 6  CTL  clone CHA-11,  specific for H-2  d 
alloantigens, had no inhibitory effect on tumor induction (Fig. 7, A and B). This 
CTL clone has been shown (7) to be active in a  specific manner against H-2  d 
tumor targets in vivo. Thus, the prevention of tumor formation was specific with 
respect to the CTL clone injected. In additional experiments, we have shown 
that  injection  of the  virus-specific CTL  clone CHM-14  has  no  effect on  the 
growth of H-2  d allogeneic tumors in the peritoneal cavities of sublethally irradi- 
ated mice, which were protected at  the same time against  M-MSV-M-MLV- 
induced tumor formation in the footpad (data not shown). 
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FIGURE 7.  Inhibition of virus-induced tumor formation by the intravenous injection of M- 
MSV-M-MLV-specific CTL clones.  Groups of five C57BL/6 female mice were irradiated 
sublethally (650 rad) and injected in the right rear footpad with 40 gl of an M-MSV-M-MLV 
stock.  Various C57BL/6  effector cells were injected intravenously immediately after virus 
injection. Experiment A: (O) 20 x  106 irradiated (2,000 rad) syngeneic spleen cells; (0) 20 × 
106  M-MSV-M-MLV-specific CTL  clone CHM-14;  (11) 20  ×  106  anti-H-2d-specific CTL 
clone CHA-11. Experiment B: (17) 20 X 106 irradiated syngeneic spleen cells; (11) 20 x  106 M- 
MSV-M-MLV-specific CTL clone MOM-I.1; (&) 20 x  106 M-MSV-M-MLV-specific CTL 
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Discussion 
M-MSV-M-MLV-specific CTL Clones.  In this report we describe the protection 
of mice against virus-induced tumors by treatment with virus-specific CTL clones. 
These same CTL clones had been shown previously to induce the destruction of 
M-MLV-induced lymphoma cells after intravenous injection (7).  Similar experi- 
ments in other systems have used either mixed populations of CTL (8, 29) or 
cloned CTL (3, 30). The availability of cloned CTL and specific antisera against 
M-MLV and Ab-X-MLV gag and env polypeptides has allowed us to characterize 
the M-MLV-encoded protein  gP85 gag as a  target  molecule recognized by the 
cloned CTL. Ab-X-MLV-infected cells deficient in the synthesis of gP85 gag were 
not lysed by the virus-specific CTL clones. The amounts of gp70  and p15  (E) 
synthesized in Ab-X-MLV- and M-MLV-infected target cells were shown to be 
indistinguishable; therefore, we believe it unlikely that the env-related  proteins 
act  as  target  molecules for  the  virus-specific CTL  clones  used  in  this  study. 
Several reports have suggested the existence of CTL  populations  specific for 
gag gene products (31-33).  Plata et al.  (33) investigated the inhibition of CTL 
activity by anti-p30 monoclonal antibodies that recognized p30 determinants on 
Friend-,  Rauscher-,  Moloney-,  and  Gross-MLV-infected  cells.  However,  the 
authors detected inhibition of cytolysis only of Gross-MLV-infected cells using 
a  mixed population  of Gross-MLV-specific CTL.  Other reports (34,  35) have 
suggested that the viral env  gene products gp70  and p15  (E) could be target 
molecules recognized by CTL, but experiments designed to detect blocking of 
CTL activity by gp70 or anti-gp70 antibodies have yielded contradictory results 
(9,  13,  14).  Flyer et al.  (10) demonstrated the existence of gp70- or p15  (E)- 
specific CTL using a mixed population of CTL and target cells transfected with 
and expressing only the M-MLV env gene. Therefore, our data suggest that both 
gag and env gene products can act as target molecules for virus-specific CTL, 
depending on the system under investigation, gP85  gag, identified in this report 
as a target molecule for M-MSV-M-MLV-specific CTL lysis, was previously (36, 
37)  shown  to  be  identical  to  the Gross  cell surface antigen (GCSA),  which is 
expressed on cells infected by viruses of the FMR group and by Gross-MLV. 
Green (32) showed a correlation between GCSA expression and susceptibility of 
Akv-induced tumor cells to CTL lysis. 
The  two  primary gag  gene  products,  gPr80 gag  and  Pr65,  are  synthesized 
independently, gPr80 gag contains all Pr65 peptides as well as 4-6 kilodaltons of 
unique amino-terminal peptides (11, 12). Several viruses, derived from or highly 
related to M-MLV, do not synthesize proteins related to M-MLV gPr80  gag (38, 
39). Since M-MLV only codes for Pr65 (40), the target molecule recognized by 
the  virus-specific  CTL  clones  must  be  encoded  exclusively by  the  M-MLV 
genome. This suggests that the observed protection of mice against M-MSV-M- 
MLV-induced tumor formation by the virus-specific cloned CTL  was due to 
selective destruction of cells infected with the virus complex, although we cannot 
exclude the influence of other factors (41) leading to the elimination of virus- 
infected cells. 
A  Possible Role for CTL in MLV-induced Leukemogenesis.  The identification of 
gP85 gag as a target molecule recognized by virus-specific CTL suggests a possible 
involvement of such CTL in the development of leukemias induced by nonleu- VAN  OER  HOORN  ET  AL.  139 
kemogenic  MLV.  Their  specific cytolytic activity  may play a  role  during  the 
selection of cells infected with recombinant  leukemogenic MLV, such as mink 
cell focus-inducing viruses (MCF) (42), during the preleukemic stage. Analysis of 
the structure of MCF viruses shows that they arose from multiple recombination 
events  between  ecotropic  and  xenotropic  MLV  (24,  43).  Based  on  previous 
studies  and  the  present  data,  the  following  model  could  account  for  their 
selection: an endogenous nonleukemogenic MLV can be expressed after birth in 
certain strains of mice (for instance Akv) (43) or, when it is injected into newborn 
mice, it can infect several organs. The MLV can recombine either with the LTR 
region  of a  xenotropic  MLV  (44,  45)  or  with  the  coding  region  of  other 
xenotropic MLV. In the latter situation (46, 47), the viraily encoded xenotropic 
cell  membrane  proteins,  such  as gPr85 g~g or gp70,  will  not be recognized  by 
specific  CTL  induced  as  a  result  of the  original  MLV  infection,  leading  to 
appearance of nonleukemogenic class II MCF viruses. In the situation where the 
original MLV recombines only with specific xenotropic Us LTR sequences, the 
resulting viruses generally will also be nonleukemogenic. Cells infected with such 
MLV will  be eliminated  by specific CTL, unless these MLV recombine further 
with  xenotropic  MLV  in  their gag,  pol,  and/or  env  regions.  Viruses  resulting 
from these secondary recombination events in the env and possibly also the gag 
region possesses the structure of leukemogenic class I  MCF viruses (24, 44). Of 
course, additional factors (e.g., antibody formation) most likely play an important 
role  in  these  and  other  steps  of MLV-induced  leukemogenesis.  In  addition, 
Chesebro  et  al.  (48)  showed  that  in  some  mouse  strains  and  cell  types,  the 
expression of MCF viruses may not be required  in ieukemogenesis.  The actual 
mechanism  of transformation  of virus-infected  target  cells is not  known.  The 
MCF  viral  env  gene  product  itself has  been  suggested  to  play a  role  in  the 
transformation  process (49,  50).  It could also stimulate the continuous recruit- 
ment of T cells, thereby enhancing the probability of spontaneous transformation 
(51). Alternatively,  the insertion  of MLV in the vicinity of oncogenes may lead 
to the activation of such genes, resulting in the transformation  of cells (52, 53). 
Some aspects of the model presented above can be tested: Are MCF-type viruses 
generated  during  MLV-induced  leukemogenesis  in  mice  that  are  unable  to 
generate  virus-specific  CTL  (41)?  Do viruses deficient  in  the  synthesis  of gag 
membrane  proteins induce leukemias in C57BL/6 mice and,  if so, what  MCF- 
type viruses, if any, can be isolated from leukemic tissues? 
Recombination  of MLV Genomes  In  Vitro.  The  antigen-loss  variants  were de- 
tected because the variants grew as ascites, while the parental tumor cells were 
eliminated by virus-specific CTL.  Emergence of antigen-loss  variants  has been 
demonstrated  both in vivo (54) and in vitro (55), but the mechanism  for their 
generation  remains  to be determined.  From  methylation  experiments we con- 
cluded that, in the revertant cell line 1/7.2R, the transcriptionally silent character 
of the  original  M-MLV  genomes  may  be  due  to  methylation  of these  viral 
genomes in vivo. Methylation events have been described both in vivo (28) and 
in  tissue  culture  (56)  that  lead  to  the  loss  of expression  of the  genes  under 
investigation. In the latter study (56) the appearance of flat revertants of Fujinami 
sarcoma virus (FSV)-transformed cells was shown to be due to hypermethylation 
of the  FSV genome in  vitro.  The authors  observed the reappearance  of trans- 140  CHARACTERIZATION OF  gP85  ~g 
formants,  again  harboring  the  FSV  genome  in  a  nonmethylated  state.  These 
retransformants resembled (56) the revertant antigen-loss variant  1/7.2R, which 
reexpressed a gag membrane protein. However, in addition to the nonmethylated 
state of some M-MLV copies in  1/7.2R cells, the insertion  of 300 bp DNA of 
unknown origin into the gag region of these M-MLV genomes was detected. The 
RNA transcribed from M-MLV genomes harboring this inserted DNA is trans- 
lated,  leading  to  the  addition  of ~100  amino  acid  residues  to  the  gPr80  g~g 
protein.  Indeed, a Pr92 protein was detected in  1/7.2R cells. Many cases of gag 
region  recombinations  in  vivo have  been  described  (57,  58),  but  were rarely 
observed in  tissue culture  (59).  The gag recombination  event  resulting  in  the 
expression of Pr92 in  1/7.2R cells most likely occurred in only one or a few ceils 
of  the  antigen-loss  variant  1/7.2R.  Recently  (Van  der  Hoorn,  unpublished 
results),  we  transmitted  virus  shed  by  1/7.2R  cells  to  C3H10T1/2  murine 
fibroblasts and  showed  the  expression  of Pr92  in  these  cells.  Therefore,  we 
believe that this virus, which probably originated in a restricted number of the 
1/7.2 R cells, spread through the culture. This would explain the CTL-susceptible 
phenotype of the 1/7.2R cells. A comparison of our data with the M-MLV DNA 
sequence shows that the insertion event occurred in the region between nucleo- 
tides 32 and 621  (26).  Molecular cloning of the virus shed by 1/7.2R cells and 
sequencing of its gag region may help to establish the origin of the inserted DNA 
and identify the initiation codon for gPr80g% 
Summary 
The gag membrane  protein  gP85  gag, encoded by Moloney murine  leukemia 
virus  (M-MLV),  was  identified  as  a  target  molecule  recognized  by  Moloney 
murine sarcoma virus-M-MLV (M-MSV-M-MLV)-specific cytolytic T  lympho- 
cyte (CTL) clones.  Target  cells infected with Ab-X-MLV, an  M-MLV-derived 
mutant virus not encoding gP85  gag, were not lysed by the CTL clones. The same 
CTL clones were shown previously to induce the destruction of M-MLV-induced 
tumor cells in the peritoneal  cavity. We have now characterized  CTL-resistant 
antigen-loss  tumor  cell  variants  that  have  lost  the  surface antigen,  but  which 
retain  transcriptionally  silent  M-MLV  genomes.  A  cloned antigen-loss  variant 
that  reverted  in  vitro  to  the  CTL-susceptible  phenotype reexpressed  M-MLV 
genomes that had undergone an insertion event in the region of the viral DNA 
coding  for  the gag  membrane  protein.  Intravenous  injection  of virus-specific 
CTL clones inhibited tumor formation in mice injected subcutaneously with M- 
MSV-M-MLV. 
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Cerottini,  and F. Plata for critically reading the manuscript. 
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